These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2525943)

  • 1. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy.
    Taha AS; McLaughlin S; Sturrock RD; Russell RI
    Br J Rheumatol; 1989 Aug; 28(4):329-32. PubMed ID: 2525943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients.
    Bianchi Porro G; Caruso I; Petrillo M; Montrone F; Ardizzone S
    J Intern Med; 1991 Jan; 229(1):5-8. PubMed ID: 1825323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins.
    Russell RI
    Rheumatol Int; 1990; 10 Suppl():17-21. PubMed ID: 2150567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.
    Taha AS; McLaughlin S; Holland PJ; Kelly RW; Sturrock RD; Russell RI
    Ann Rheum Dis; 1990 Jun; 49(6):354-8. PubMed ID: 2143369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
    Bianchi Porro G; Lazzaroni M; Petrillo M
    Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa.
    Lanza F; Rack MF; Lynn M; Wolf J; Sanda M
    J Rheumatol; 1987 Apr; 14(2):338-41. PubMed ID: 2955117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa.
    van Eeden A; Schotborgh RH; Tytgat GN
    Clin Ther; 1990; 12(6):496-502. PubMed ID: 2149673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
    Bianchi Porro G; Montrone F; Petrillo M; Caruso I; Imbesi V
    Am J Gastroenterol; 1995 Sep; 90(9):1485-8. PubMed ID: 7661175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis.
    de Queiros MF
    Clin Ther; 1991; 13(1):38-46. PubMed ID: 1827613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A global safety evaluation of etodolac.
    Karbowski A
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():73-9. PubMed ID: 2525986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy.
    Roth SH
    Am J Med; 1987 Oct; 83(4B):25-30. PubMed ID: 3318424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of severe gastric damage as a result of pirprofen and naproxen treatment in rheumatoid arthritis: a controlled endoscopic study.
    Montrone F; Petrillo M; Caruso I; Bianchi Porro G
    J Intern Med; 1994 Aug; 236(2):153-9. PubMed ID: 8046314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study.
    Waltham-Weeks CD
    Curr Med Res Opin; 1987; 10(8):540-7. PubMed ID: 2960494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production.
    Laine L; Sloane R; Ferretti M; Cominelli F
    Gastrointest Endosc; 1995 Nov; 42(5):428-33. PubMed ID: 8566633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric mucosal adaptation to etodolac and naproxen.
    Lipscomb GR; Wallis N; Armstrong G; Goodman MJ; Rees WD
    Aliment Pharmacol Ther; 1995 Aug; 9(4):379-85. PubMed ID: 8527613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, parallel-group evaluation of etodolac and naproxen in patients with acute sports injuries.
    D'Hooghe M
    Clin Ther; 1992; 14(4):507-16. PubMed ID: 1388091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal assessment of gastrointestinal side effects induced by non-steroidal anti-inflammatory drugs. Endoscopic lesions, faecal blood loss, and symptoms not necessarily correlated, as observed after naproxen and oxindanac in healthy volunteers.
    Aabakken L; Dybdahl JH; Eidsaunet W; Haaland A; Larsen S; Osnes M
    Scand J Gastroenterol; 1989 Oct; 24(8):1007-13. PubMed ID: 2688064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the antiarthritic efficacy and safety of etodolac.
    Zvaifler N
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():43-53. PubMed ID: 2525982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies.
    Lanza FL; Arnold JD
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():5-15. PubMed ID: 2525983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.